Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AD/PD 2022 | Plans to reduce sampling bias in the ADNI project

Michael Weiner, MD, University of California, San Francisco, San Francisco, CA, discusses how they plan on avoiding sampling bias in ADNI by taking a different approach when recruiting participants. In the past, each ADNI site was responsible for identifying people and enrolling people in the study. Going forward, a very ambitious social media plan will help the ADNI sites recruit participants. The social media campaign’s goals are to educate the population, reduce mistrust, and increase interest in participation in Alzheimer’s disease research. Digital advertising will be used to drive people to websites tailored to each under-represented population and ADNI site. After enrolling through the local ADNI website, if the participant appears to be eligible for the study, blood samples will be taken and analyzed for Alzheimer’s disease biomarkers. Then, during patient selection, priority will be given to Black and Latino individuals, those with mild cognitive impartment or even dementia, and those with positive Alzheimer’s disease biomarkers. Hopefully, the ADNI project will improve diagnostics and, ultimately, the prevention of Alzheimer’s disease and be a model for future clinical trials. This interview took place at the AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases hosted in Barcelona, Spain.